We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In his State of the Union address on Tuesday, President Joe Biden reiterated his desire to drive down the price of pharmaceuticals in the U.S., a move that was thwarted in January after his massive spending package Build Back Better plan didn’t make it through the Senate. Read More
Sanofi reported that the average net price in its U.S. drugs after rebates and discounts decreased by 1.3 percent in 2021, continuing a six-year downward trend. Read More
Christopher A. Williamson, president of Vital Health and Wellness, received a Feb. 15 warning letter from the FDA stating that ingredients in the product Dr. Miller’s Holistic Premium Holy Tea are marketed for use in the cure, mitigation, treatment or prevention of disease. Read More
The FDA is making moves to improve how oncology trials are designed and conducted, publishing three final guidances on master protocol trials, first-in-human trials with expansion cohorts and the inclusion of older patients in earlier-phase cancer trials. Read More
Dozens of leaders in the global life sciences community are among the many who have signed an open letter condemning Russia’s invasion of Ukraine, calling it a “barbaric act that will lead to substantial loss of life, trauma to millions of people and the dislocation of civil society in a nation that has repeatedly expressed its peaceful intentions.” Read More
A U.S. Patent and Trademark Office tribunal that oversees patent disputes has ruled that patents on CRISPR technology belong to Harvard University and the Massachusetts Institute of Technology’s Broad Institute — not to Jennifer Doudna of the University of California, Berkeley, and Emmanuelle Charpentier of the Max Planck Institute for Infection Biology, who were given the Nobel Prize in Chemistry in 2020 for first describing how CRISPR could be used to edit DNA in test-tube environments. Read More
The FDA has issued a Complete Response Letter (CRL) to Gilead Sciences for its new drug application (NDA) for lenacapavir, an HIV-1 capsid inhibitor for patients with HIV who are heavily treated and multidrug-resistant. Read More
The Cambridge, Mass., drugmaker earned $18.5 billion in total revenue for 2021, almost all of which was from sales of its coronavirus vaccine. Read More